SerImmune reveals the compositions of functional immune repertoires, creating new opportunities for therapeutic and diagnostic development. SerImmune maps the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases, and cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/21/17 | $8,000,000 |
Illumina Ventures Merck | undisclosed |
